Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | JUN | P05412 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | GLS | O94925 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30660236 | 1.00 | HSD17B10 (0.73) | HSD17B10MEN1KMT2AIDO1ADRA1A | |
| SCHEMBL1097812 | 0.86 | KMT2A (0.56) | HSD17B10MEN1KMT2A | |
| SCHEMBL1032357 | 0.86 | HSD17B10 (0.73) | HSD17B10MEN1KMT2AIDO1ADRA1A | |
| SCHEMBL5743959 | 0.84 | HSD17B10 (0.75) | HSD17B10MEN1KMT2AIDO1ADRA1A | |
| SCHEMBL30512021 | 0.84 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AIDO1ADRA1A | |
| SCHEMBL504029 | 0.84 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AIDO1ADRA1A | |
| SCHEMBL3007023 | 0.83 | HSD17B10 (0.69) | HSD17B10MEN1KMT2AIDO1ADRA1A | |
| SCHEMBL16836022 | 0.83 | HSD17B10 (0.50) | HSD17B10HTR2A | |
| Hydrochloric Acid SCHEMBL2527402 | 0.83 | HSD17B10 (0.97) | HSD17B10MEN1KMT2AIDO1ADRA1A | |
| SCHEMBL8237110 | 0.83 | HSD17B10 (0.50) | HSD17B10MEN1KMT2AMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024298-A | Tertiary amide compound containing naphthyl and its preparation method and application | 北京中医药大学 | 2023-11-10 | — | — | CN | claimed |
| EP-3965738-B1 | METHOD FOR PRODUCTION OF LIPOSOMES | UNIV DO MINHO (PT) | 2025-08-06 | — | — | EP | disclosed |
| CN-117024298-A | Tertiary amide compound containing naphthyl and its preparation method and application | 北京中医药大学 | 2023-11-10 | — | — | CN | disclosed |
| US-20220241203-A1 | METHOD FOR PRODUCTION OF LIPOSOMES | UNIVERSIDADE DO MINHO (PT) | 2022-08-04 | — | — | US | disclosed |
| EP-3190109-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2020-02-19 | — | — | EP | disclosed |
| EP-3348550-B1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | CONSEJO SUPERIOR INVESTIGACION (ES) | 2019-04-24 | — | — | EP | disclosed |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | REMYND (BE) | 2019-02-21 | — | — | US | disclosed |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-3348550-A1 | SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2018-07-18 | — | — | EP | disclosed |
| US-9765053-B2 | Methods of treatment using selective 5-HT2A inverse agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-09-19 | — | — | US | disclosed |
| WO-1996030377-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0698010-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-28 | — | — | EP | disclosed |
| US-5491172-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| US-5470854-A | Antiestrogens | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-11-28 | — | — | US | disclosed |
| WO-1994026702-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0169537-B1 | 2-PHENYLALKYL-3-AMINOALKYL-4(3H)-QUINAZOLINONES, PROCESSES FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS AND USE | MITSUBISHI KASEI CORPORATION (JP) | 1990-01-03 | — | — | EP | disclosed |
| US-4668682-A | CALCIUM ANTAGONISTS, VASODILATORS, HYPOTENSIVE AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1987-05-26 | — | — | US | disclosed |
| EP-0169537-A2 | 2-Phenylalkyl-3-aminoalkyl-4(3H)-quinazolinones, processes for preparing them, pharmaceutical compositions and use | MITSUBISHI KASEI CORPORATION (JP) | 1986-01-29 | — | — | EP | disclosed |
| EP-0017376-A1 | Phenylacetamide compounds and an analgesic composition containing them | KISSEI PHARMACEUTICAL CO. LTD (JP) | 1980-10-15 | — | — | EP | disclosed |
| US-3950236-A | OXIDATION, ALKYL-ALKOXY-BIBENZYL COMPOUNDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH, EDUCATION AND WELFARE (US) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | SNCA, MAPT, NLN | HSD17B10 2592/4885MEN1 3335/4885KMT2A 2251/4885 |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | SNCA, MAPT, NLN | HSD17B10 2603/4885MEN1 3452/4885KMT2A 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.